UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Erratum: Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

The American journal of gastroenterology, 2010-03, Vol.105 (3), p.500-500

2010

Volltextzugriff (PDF)

Adalimumab: Another Treatment Option for Moderate-to-Severe UC

Gastroenterology & hepatology, 2013-05, Vol.9 (5), p.321-321

Kornbluth, Asher A

2013

Volltextzugriff (PDF)

The First Endoscopy in Suspected Inflammatory Bowel Disease

Gastrointestinal endoscopy clinics of North America, 2016-10, Vol.26 (4), p.593-610

2016

Volltextzugriff (PDF)

Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference

Inflammatory bowel diseases, 1998-11, Vol.4 (4), p.328-329

Kornbluth, A

1998

Volltextzugriff (PDF)

Mucosal Dysplasia in Ileal Pelvic Pouches After Restorative Proctocolectomy

Diseases of the colon & rectum, 2007-06, Vol.50 (6), p.825-831

2007

Volltextzugriff (PDF)

Positioning Therapy for Ulcerative Colitis

Current gastroenterology reports, 2015-08, Vol.17 (8), p.29-29, Article 29

2015

Volltextzugriff (PDF)

Budesonide Extended-Release in Patients With Mild to Moderate Ulcerative Colitis

Gastroenterology & hepatology, 2015-01, Vol.11 (1), p.56-58

Kornbluth, Asher

2015

Volltextzugriff (PDF)

Mucosal Healing in Inflammatory Bowel Disease: Where Do We Stand?

Current gastroenterology reports, 2010-12, Vol.12 (6), p.471-478

2010

Volltextzugriff (PDF)

COVID-19 INFECTIONS IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: OUTCOMES AND RISK FACTORS FOR SEVERE DISEASE

Gastroenterology (New York, N.Y. 1943), 2022-02, Vol.162 (3), p.S104-S105

2022

Volltextzugriff (PDF)

Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis

Gastroenterology & hepatology, 2014-12, Vol.10 (12), p.793-800

2014

Volltextzugriff (PDF)

Effectiveness and Safety of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease

Gastroenterology & hepatology, 2022-03, Vol.18 (3), p.145-155

2022

Volltextzugriff (PDF)

COVID-19 INFECTIONS IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: OUTCOMES AND RISK FACTORS FOR SEVERE DISEASE

Inflammatory bowel diseases, 2022-01, Vol.28 (Supplement_1), p.S104-S105

2022

Volltextzugriff (PDF)

Su1493: COVID-19 RELATED THROMBOTIC, CARDIOVASCULAR, AND RENAL COMPLICATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM AN INTERNATIONAL REGISTRY

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-599-S-599

2022

Volltextzugriff (PDF)

Cyclosporine versus infliximab for the treatment of severe ulcerative colitis

Gastroenterology & hepatology, 2011-10, Vol.7 (10), p.677-679

Kornbluth, Asher

2011

Volltextzugriff (PDF)

The Rising Epidemic of Obesity in Patients with Inflammatory Bowel Disease

Current treatment options in gastroenterology, 2024-06, Vol.22 (3), p.134-144

2024

Volltextzugriff (PDF)

Su1556: MATERNAL INFLAMMATORY BOWEL DISEASE DIAGNOSIS BUT NOT GENETIC DETERMINANTS OF THE DISEASE RISK PREDICT FECAL CALPROTECTIN LEVELS DURING EARLY LIFE

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-629-S-629

2022

Volltextzugriff (PDF)

Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19

Journal of Crohn's & colitis, 2020-10, Vol.14 (Supplement_3), p.S769-S773

2020

Volltextzugriff (PDF)

164 - Vedolizumab Therapy Induces a Redistribution of CD4+ T Cells to Uninvolved Intestinal Mucosa in Patients with Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-46-S-46

2018

Volltextzugriff (PDF)

Treatment responses in collagenous colitis

The American journal of gastroenterology, 2001, Vol.96 (3), p.818-821

2001

Volltextzugriff (PDF)

Mo1832 - Baseline Level of Integrin A4B7 on Circulating Plasmablasts Predicts Response to Vedolizumab in Patients with Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-818-S-818

2018

Volltextzugriff (PDF)

P-106 Evaluation of the Association Between Fecal Lactoferrin Status and Clinical, Serologic and Endoscopic Outcomes: Post-Hoc Analysis of the Sonic Trial

Inflammatory bowel diseases, 2014-12, Vol.20, p.S71

2014

Volltextzugriff (PDF)

Infants Born to Mothers with Inflammatory Bowel Disease Exhibit Distinct Microbiome Features that Persist Up to 3 Months of Life

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S193-S193

2017

Volltextzugriff (PDF)

1062 - Infants Born to Mothers with Inflammatory Bowel Disease Exhibit Distinct Microbiome Features that Persist Up to 3 Months of Life

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S193-S193

2017

Volltextzugriff (PDF)

Su1907 Exploring MEChanisms of IBD traNsmission In Utero through the Microbiome: The MECONIUM Study Pilot

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S585-S585

2016

Volltextzugriff (PDF)

What happened to drug trials in ulcerative colitis? problems, PPARs, placebos, and (possible) progress

The American journal of gastroenterology, 2001, Vol.96 (12), p.3232-3234

Kornbluth, Asher

2001

Volltextzugriff (PDF)

1 – 25 von 76

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(48)

Publikationsform

Artikel
(75)
Buchkapitel
(1)

Sprache

Englisch
(76)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Erratum: Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

Adalimumab: Another Treatment Option for Moderate-to-Severe UC

The First Endoscopy in Suspected Inflammatory Bowel Disease

Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference

Mucosal Dysplasia in Ileal Pelvic Pouches After Restorative Proctocolectomy

Positioning Therapy for Ulcerative Colitis

Budesonide Extended-Release in Patients With Mild to Moderate Ulcerative Colitis

Mucosal Healing in Inflammatory Bowel Disease: Where Do We Stand?

COVID-19 INFECTIONS IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: OUTCOMES AND RISK FACTORS FOR SEVERE DISEASE

Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis

Effectiveness and Safety of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease

COVID-19 INFECTIONS IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: OUTCOMES AND RISK FACTORS FOR SEVERE DISEASE

Su1493: COVID-19 RELATED THROMBOTIC, CARDIOVASCULAR, AND RENAL COMPLICATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM AN INTERNATIONAL REGISTRY

Cyclosporine versus infliximab for the treatment of severe ulcerative colitis

The Rising Epidemic of Obesity in Patients with Inflammatory Bowel Disease

Su1556: MATERNAL INFLAMMATORY BOWEL DISEASE DIAGNOSIS BUT NOT GENETIC DETERMINANTS OF THE DISEASE RISK PREDICT FECAL CALPROTECTIN LEVELS DURING EARLY LIFE

Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19

164 - Vedolizumab Therapy Induces a Redistribution of CD4+ T Cells to Uninvolved Intestinal Mucosa in Patients with Inflammatory Bowel Disease

Treatment responses in collagenous colitis

Mo1832 - Baseline Level of Integrin A4B7 on Circulating Plasmablasts Predicts Response to Vedolizumab in Patients with Inflammatory Bowel Disease

P-106 Evaluation of the Association Between Fecal Lactoferrin Status and Clinical, Serologic and Endoscopic Outcomes: Post-Hoc Analysis of the Sonic Trial

Infants Born to Mothers with Inflammatory Bowel Disease Exhibit Distinct Microbiome Features that Persist Up to 3 Months of Life

1062 - Infants Born to Mothers with Inflammatory Bowel Disease Exhibit Distinct Microbiome Features that Persist Up to 3 Months of Life

Su1907 Exploring MEChanisms of IBD traNsmission In Utero through the Microbiome: The MECONIUM Study Pilot

What happened to drug trials in ulcerative colitis? problems, PPARs, placebos, and (possible) progress

Aktive Filter

Suchergebnisse filtern